American College of Clinical Pharmacy
      Search      Cart
         

Ambulatory Care PRN Focus Session -- Taking Your Patients’ Health to Heart: A Case-based Approach to Assess, Prevent, and Manage ASCVD

Sunday, October 27, 2019 from 4:00 PM to 5:30 PM EST

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-179-L01-P
Activity Type: An Application-Based Activity


Speakers
So You’re Saying There’s a Chance?! Estimating ASCVD Risk
4:00 PM

Speakers
  • Elizabeth T. Renner, Pharm.D., BCPS, BCACP, CACPSpeaker: Elizabeth T. Renner, Pharm.D., BCPS, BCACP, CACP
    Clinical Pharmacist-Outpatient Cardiology at University of Michigan Health System, Ann Arbor, Michigan
      View Biography


Learning Objectives
1. Compare various calculators including the ACC/AHA Risk Estimator and the Pooled Cohort Equations to estimate ASCVD risk.
2. Apply various ASCVD risk calculators to a standardized patient case.
ASPIRINing for an Answer: Delving into the Latest Evidence on Aspirin for Primary Prevention
4:30 PM

Speakers
  • Joel C. Marrs, PharmD, FNLA, BCPS (AQ Cardiology), CLSSpeaker: Joel C. Marrs, PharmD, FNLA, BCPS (AQ Cardiology), CLS
    Associate Professor, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado
      View Biography


Learning Objectives
1. Discuss recent literature regarding aspirin use for primary prevention of ASCVD.
2. Recommend judicious initiation, continuation and discontinuation of aspirin for primary prevention of ASCVD given patient specific factors.
Evaluating the Updated 2018 ACC/AHA Cholesterol Guidelines
4:55 PM

Speakers
  • Dave L. Dixon, Pharm.D.,BCPS,FCCPSpeaker: Dave L. Dixon, Pharm.D.,BCPS,FCCP
    Associate Professor, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia
      View Biography


Learning Objectives
1. Recall important updates to the 2018 version of the ACC/AHA cholesterol guidelines from previous versions.
2. Critique the updated ACC/AHA cholesterol guideline recommendations to incorporating LDL thresholds using available literature.
3. Evaluate the updated ACC/AHA cholesterol guideline recommendation of utilizing non-statin therapies for ASCVD prevention and treatment by reviewing available evidence.
Question and Answer
5:20 PM